Nicox Secures a €6M Shareholder Loan over 3 Years with Vester Finance
Nicox announced on Tuesday the signing of a shareholder loan agreement with Vester Finance for €6 million over 36 months. This optional financing aims to support the biotech's strategic opportunities while preserving its capital structure.
A Shareholder Loan to Fund Strategic Initiatives
Nicox and Vester Finance have concluded a shareholder loan agreement signed on June 22, 2026, providing the company with additional resources of up to €6M over a three-year period. The arrangement operates on the basis of successive advances, each capped at €500K, which Nicox can request at its discretion without any obligation to draw.
Repayment in Shares or Cash, with a Dilution Cap
Advances can be repaid either by subscribing to new shares issued by Nicox or in cash. In the case of repayment in shares, the issuance will be based on the lower of the two daily volume-weighted average prices preceding each issue, reduced by a maximum discount of 6.5%, up to a limit of 15 million new shares.
Clinical Advancements and Strategic Flexibility
Gavin Spencer, CEO of Nicox, stated that this financing line offers additional flexibility to explore strategic opportunities while maintaining a stable capital base. Nicox emphasizes that this shareholder operation functions in parallel with the unsecured bond financing announced on January 5, 2026.
